ALNY FY2025 SEC EDGAR DEF 14A #72 of 168 in industry

Alnylam Pharmaceuticals, Inc. CEO pay ratio

The CEO earned $15.0M in FY2025 against median worker pay of $312,180 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
MA
Filing date
2026-04-06
Industry
Chemicals & Pharmaceuticals
Industry rank
#72/168

Data updated August 2026

Subscribe to Alnylam Pharmaceuticals, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
48:1
Below Average (Scale: 0–1000:1)
CEO pay
$15.0M
Median worker
$312,180

Answer first

Alnylam Pharmaceuticals, Inc.'s FY2025 CEO total of $15.0M ranks #308 of 1,423 complete filings; its 48:1 pay ratio ranks #983. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $312,180. Industry placement uses the FY2025 SIC-28 peer cohort (# 72 of 168, 58th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#308
$15.0M of 1,423 FY2025
Ratio rank
#983
48:1 of 1,423
Industry pct
58th
above the industry median pay ratio

How Alnylam Pharmaceuticals, Inc. ranks nationally

Alnylam Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$14,984,640 Top 22% higher than 78% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Alnylam Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($15.0M) against pay ratio (48:1) for Alnylam Pharmaceuticals, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both2820634.87652567.612484500.517316433.422148366.341.6:143.6:145.5:147.4:149.4:1CEO total payPay ratio (CEO : median worker)Alnylam Pharmaceuticals, Inc., CEO total pay: 14984640 · Pay ratio (CEO : median worker): 48:1Alnylam Pharmaceuticals, Inc.Vaxcyte, Inc., CEO total pay: 14585904 · Pay ratio (CEO : median worker): 48:1Vaxcyte, Inc.Valhi Inc /de/, CEO total pay: 3699168 · Pay ratio (CEO : median worker): 48:1Valhi Inc /de/Madrigal Pharmaceuticals, Inc., CEO total pay: 18959941 · Pay ratio (CEO : median worker): 47:1Madrigal Pharmaceuticals, Inc.Adaptive Biotechnologies Corp, CEO total pay: 9147140 · Pay ratio (CEO : median worker): 47:1Adaptive Biotechnologies CorpViking Therapeutics, Inc., CEO total pay: 21269833 · Pay ratio (CEO : median worker): 49:1Viking Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Alnylam Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Alnylam Pharmaceuticals, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
48:1
FY2025
vs prior FY
+9:1
from FY2024 39:1
CEO $ YoY
+29%
$15.0M latest
Filings shown
5
FY2021–2025
Alnylam Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $10.2M - $231,163 44:1 -
2022 $4.5M -56% $237,547 19:1 -25:1
2023 $8.9M +98% $255,415 35:1 +16:1
2024 $11.6M +30% $297,040 39:1 +4:1
2025 $15.0M +29% $312,180 48:1 +9:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1178670, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
48:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$15.0M
Companies in Industry
168
vs. Industry Median
Above
#72 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Alnylam Pharmaceuticals, Inc.: MODEST · HEAVY pay ratio

Alnylam Pharmaceuticals, Inc.'s FY2025 CEO total $15.0M ranks #308 of 1,423 complete filings (higher third by dollars). the CEO earned 48× the median employee ($312,180) in FY2025.

Median employee $312,180 (ELITE-MED); MODEST · HEAVY stamps put about 48 median-wage years per CEO year.

CEO Total Pay

$15.0M

FY2025 Summary Compensation, above median

Pay Ratio

48:1

Below typical

Alnylam Pharmaceuticals, Inc. in the higher-dollar third

Alnylam Pharmaceuticals, Inc.'s FY2025 CEO total $15.0M ranks #308 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Alnylam Pharmaceuticals, Inc.'s $15.0M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #308 and ratio rank #983 split - treat 48:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$15.0M
Median Employee Pay
$312,180
Pay Ratio
48:1
Filing Date
2026-04-06

Company Info

Ticker
ALNY
CIK
1178670
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
MA
View SEC filings →
SEC EDGAR DEF 14A for CIK 1178670, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Alnylam Pharmaceuticals, Inc.'s FY2025 CEO total $15.0M ranks #308 of 1,423 complete filings (higher third by dollars).

Read with Alnylam Pharmaceuticals, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Elanco Animal Health Inc · HEAVY

ABS(ceo_total_comp) peer at $15.0M (Δ $20K lighter vs Alnylam Pharmaceuticals, Inc.); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Nicolet Bankshares Inc · HEAVY

ABS(ceo_total_comp) peer at $15.0M (Δ $21K lighter vs Alnylam Pharmaceuticals, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Janus Henderson Group Ltd. · PEAK

ABS(ceo_total_comp) peer at $15.0M (Δ $22K heavier vs Alnylam Pharmaceuticals, Inc.); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Eversource Energy · PEAK

ABS(ceo_total_comp) peer at $15.0M (Δ $26K heavier vs Alnylam Pharmaceuticals, Inc.); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Vaxcyte, Inc. (SIC 28 pole)

Vaxcyte, Inc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Alnylam Pharmaceuticals, Inc.'s MODEST filing.
National dual ranks · #308/#983

Alnylam Pharmaceuticals, Inc.'s FY2025 package sits #308 by CEO dollars and #983 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Alnylam Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Alnylam Pharmaceuticals, Inc. (CIK 1178670), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.